H.B. Fuller Company (FUL) Q4 2023 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2023 earnings summary
15 Oct, 2026Executive summary
Q4 adjusted EBITDA rose 22% YoY to $173M; adjusted EPS increased 27% to $1.32, and adjusted EBITDA margin reached a record 19.1%.
FY23 adjusted EBITDA margin set a record at 16.5%; operating cash flow rose 48% YoY to $378M.
Pricing, raw-material cost actions, restructuring and cost reductions supported margin expansion; customer destocking was viewed as largely behind the business.
FY24 priorities include high-return growth opportunities, innovation, manufacturing efficiencies and acquisition synergies.
Financial highlights
Q4 net revenue was $903M, down 5.8% YoY; on a comparable 13-week basis it rose 1.2%, while organic revenue declined 3.5%.
Q4 adjusted gross margin was 31.3%, up 510 bps YoY and 130 bps sequentially; adjusted SG&A was effectively flat YoY.
Q4 net income was $45M and adjusted net income was $74M; reported diluted EPS was $0.80 versus adjusted diluted EPS of $1.32.
FY revenue was $3.51B, down 6.4%; organic revenue fell 5.5%, with volume down 8.4% and pricing up 2.9%.
FY adjusted EBITDA was $581M, up 10%; adjusted diluted EPS was $3.87.
Outlook and guidance
FY24 net revenue is expected to rise 3%–6% and organic revenue 1%–3%; volume is expected up low-to-mid single digits, with pricing down low single digits.
FY24 adjusted EBITDA guidance is $610M–$640M, up 5%–10%; volume growth, restructuring savings and acquisitions are expected to more than offset inflation and rebuilding variable compensation.
FY24 adjusted EPS is expected at $4.15–$4.45, up 7%–15%; net interest expense is $115M–$125M, core tax rate 27%–28% and diluted share count ~57M.
FY24 operating cash flow is expected at $300M–$350M, weighted to 2H; D&A is ~ $170M and capex ~ $140M. Q1 net revenue is expected up low single digits and adjusted EBITDA at $115M–$125M.
Long-term target is adjusted EBITDA margin above 20% within 3–5 years; FY24 outlook anticipates positive organic growth and further margin expansion.
Latest events from H.B. Fuller Company
- Acquisition accelerates medical growth, expands TAM to ~$95B, and targets $55M in synergies.FUL
Acquisition presentation - Q3 net revenue up 5.2%, record 19.9% EBITDA margin, and raised 2026 guidance.FUL
Q3 2026 - Q2 2026 saw strong revenue, margin, and EPS growth, with a major medical acquisition announced.FUL
Q2 2026 - All proposals passed, including director elections and auditor ratification, with no shareholder questions.FUL
AGM 2026 - Adjusted EBITDA and EPS rose with margin expansion despite a 6.6% organic revenue decline.FUL
Q1 2026 - Proxy covers director elections, auditor ratification, pay, strong results, and ESG focus.FUL
Proxy Filing - Votes will be cast for director elections, auditor ratification, and executive pay approval.FUL
Proxy Filing - Adjusted EBITDA and EPS grew 5% year-over-year, with margin gains and raised full-year guidance.FUL
Q2 2025 - Q3 2024 saw 6% EBITDA and 7% EPS growth, led by strong Construction Adhesives results.FUL
Q3 2024